

Recent Modalities in Management of Gastrointestinal Stromal Tumors

Essay

*Submitted in partial fulfillment for the
Master Degree in General Surgery*

By

Omar Ahmed Mahmoud Mohamed

M. B. B.Ch.

Faculty of Medicine, Assuit University

Supervised by

Prof. Dr. Mohamed Ahmed Mohamed Khalaf

Professor of General surgery

Faculty of Medicine, Ain Shams University

Dr. Walid Ibrahim AbdRabuh

Assistant professor of General surgery

Faculty of Medicine, Ain Shams University

Dr. Mostafa Abdoh Mohamed

Assistant professor of General Surgery

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain-Shams University

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَأَنْزَلَ اللَّهُ عَلَيْكَ
الْكِتَابَ وَالْحِكْمَةَ
وَعَلَّمَكَ مَا لَمْ تَكُنْ
تَعْلَمُ وَكَانَ فَضْلُ
اللَّهِ عَلَيْكَ عَظِيمًا

صدق الله العظيم

سورة النساء الآية (١١٢)



*First thanks to **Allah** to whom I relate any success in achieving any work in my life.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr Mohamed Ahmed Mohamed Khalaf** professor of General Surgery, Faculty of Medicine, Ain Shams University for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*I would like to express my sincere appreciation and deepest gratitude to **Dr. Walid Ibrahim Abd Rabuh** Assistant professor of General surgery Faculty of Medicine, Ain Shams University*

*I am deeply thankful to **Dr. Mostafa Abdo**, Assistant professor of General surgery Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

*✍ **Omar Ahmed Mahmoud Mohamed***

List of Contents

<i>Title</i>	<i>Page No.</i>
List of Tables	ii
List of Figures	iii
List of Abbreviations.....	vi
Introduction	- 1 -
Aim Of The Work	- 8 -
Review of literature	
(Chapter 1): Histopathology Of Gist.....	- 9 -
(Chapter 2):Diagnosis Of Gastrointestinal Stromal Tumors.....	- 17 -
Clinical presentations	-17-
Rare Presentations	-19-
Investigations.....	-23-
(Chapter 3):Treatment Of Gastrointestinal Stromal Tumors.....	- 41 -
Surgical Treatment	- 41 -
Targeted Medical Therapy In Gist	- 62 -
Surveillance And Prognostic Fueture	- 69 -
Summary.....	- 79 -
References	- 85 -
Arabic summary	--

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Recommended immunohistochemical markers for gastro-intestinal stromal tumors (GISTs) and other immuno-reactive tumors	16 -
Table (2):	Risk Stratification of Primary GIST by Mitotic Index, Size, and Site. Data are based on long-term follow-up of 1055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal GISTs. Abbreviations: GIST, gastrointestinal stromal tumor; HPF, high-power field. Denotes small numbers of cases	23 -
Table (3):	NIH Risk stratification of primary GIST according to tumour size and mitotic activity, a consensus approach 2002 (HPF corresponding to 5 mm ²)	70 -

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Gross appearances of gastric GISTs.....	11 -
Figure (2):	A large exophytic gastric GIST arises from the greater curve.	25 -
Figure (3):	Endoscopic image of GIST in fundus of stomach, seen on retroflexion.....	26 -
Figure (4):	Same GIST seen on forward view of the endoscope showing overlying clot&ulceration..	26 -
Figure (5):	a large exophytic gastric GIST arises from the greater curve.	27 -
Figure (6):	Left parasagittal view of Trans rectal sonography shows an exophytic hypoechoic mass arising from the anterolateral wall of rectum.	28 -
Figure (7):	Gastric GIST over the lesser curve. Barium meal shows a typical submucosal lesion with overlying mucosal ulceration.	29 -
Figure (8):	Gastrointestinal stromal tumor with central bull's eye appearance.....	29 -
Figure (9):	Representative morphological findings in a gastric GIST. A: Preoperative CT scan. B: The same tumor after partial gastric resection.....	30 -
Figure (10):	Gastric GIST arises from greater curve. Corresponding contrast-enhanced axial CT	32 -
Figure (11):	Jejunal GIST. A moderately contrast-enhancing soft-tissue mass	33 -
Figure (12):	Gastric GIST. A large exogastric heterogeneous mass sits in close proximity to the posterior gastric wall.....	34 -
Figure (13):	Ileal GIST presented with intermittent gastrointestinal bleeding. Superior mesenteric angiography shows a hypervascular mass	38 -

List of Figures (Con)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (14):	outlines a proposed treatment algorithm for patients who are diagnosed with GIST in the Imatinib era.....	- 43 -
Figure (15):	A gastric stromal tumor treated by endoscopic mucosal resection.	- 46 -
Figure (16):	GIST: (A)CECT scan of a large dimension GIST invading adjacent transverse colon (B). macroscopic aspect of the surgical specimen with R0 resection.....	- 50 -
Figure (17):	A gastric stromal tumor treated by endoscopy.	- 52 -
Figure (18):	A mass in rectum was GIST	- 56 -
Figure (19):	Midline incision for trans-sacral local resection. Skin over sacrum was incised and extended to the point between coccyx and anus	- 57 -
Figure (20):	Procedure of gastroscopic resection of the lesion.....	- 59 -

List of Abbreviations

AFIP	: Armed forces institute of pathology
ATP	:adenosine triphosphate
CD	:Cluster of differentiation
CECT	:contrast enhanced computed tomography
CR	: Complete response
DFS	:Disease free survival
DSS	:disease-specific survival
EGISTs	:Extra gastrointestinal stromal tumors
EUS	:Endoscopic ultrasonography
ESMO	:European society of medical oncology
FDG	:fluoro-2-deoxy-D-glucose
FNA	:fine needle aspiration
GI	:Gastrointestinal
GISTS	:Gastrointestinal stromal tumors
GIST/Ls	:Gastrointestinal stromal tumors and leiomyoma's
GIT	:Gastrointestinal tract
HAE	:Hepatic arterial embolization
HPF	:High power field
ICCs	:Interstitial cells of Cajal
IHC	:Immunohistochemistry
IM	:Imatinib Mesylate
LMP	:Low malignant potential
MRI	:Magnetic resonanc image
NCCN	:National Comprehensive Cancer Network
NF1	:Neurofibromatosis type one
OS	:Overall survival
PDGFRα	:Platelet-derived growth factor receptor alpha
PET	:Positron Emission Tomography
PFS	:Progression-free survival
RFS	:recurrence-free survival
RR	:Response rate
SDH	:succinate dehydrogenase
SMA	:Smooth muscle actin
VCE	:Video capsule endoscope

INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract (*Demetri et al., 2007*).

GISTs are rare, accounting for only 1% to 3% of all malignant gastrointestinal tumors and only (*Lamba et al., 2012*). The annual incidence of GIST is 11 - 14/million annually and the median age of diagnosis is 60 years (range 51 - 60)(*Rammohan et al., 2013*).

These tumors are very rare in the pediatric population, with <1% occurring prior to age 21(*Miettinen and Lasota, 2013*).

Mesenchymal tumors are a family of related tumors including those named plexosarcomas, leiomyoblastomas, leiomyosarcomas, GISTs, gastrointestinal autonomic tumors (GANTs), and gastrointestinal pacemaker cell tumors (GIPACTs) (*Megan et al., 2004*).

The first accurate description of mesenchymal neoplasms of the gastrointestinal tract (GIT) was in 1941. Traditionally, these tumors were thought to be derived from smooth muscle cells, based on their resemblance to smooth muscle tumors and they were designated as leiomyomas, bizarre leiomyomas, cellular leiomyomas and leiomyosarcomas. However, with the advent of electron

microscopy, it has been shown that relatively few neoplasms showed convincing ultrastructural evidence of smooth muscle differentiation. The application of immunohistochemistry revealed that many of these neoplasms lacked the immunophenotypical features of smooth muscle differentiation (***Muna et al., 2005***).

The term Gastrointestinal stromal tumors (GISTs) was first used, and includes a heterogeneous group of non epithelial neoplasms with spindle or epithelioid cells, which may display myogenic features (smooth muscle GISTs), neural attributes (gastrointestinal autonomic nerve tumor), or characteristics of both muscle and nerve (mixed GISTs), or may lack differentiation (GISTs not otherwise specified) (***Nikolaos et al., 2005***).

Subsequently, the concept of ‘plexosarcoma’ with the existence of a small subset of stromal tumors with autonomic neuronal differentiation, became better known as gastrointestinal autonomic nerve tumors (GANTs) (***Muna et al., 2005***).

With the advent of immunohistochemical analysis a definition of a new entity among the gastrointestinal mesenchymal tumors called the gastrointestinal stromal tumors (GISTs) which particularly express the c-kit (CD117) protein a growth factor trans-membrane receptor with tyrosine kinase activity (***Daniel et al., 2005***).

They may occur anywhere along the length of the digestive tract from the esophagus to the anus. They account for approximately 1-3% of gastric neoplasms, 2% of small bowel tumors and 0.2-1% of colorectal tumors. Approximately 60-70% of the GISTs arises in the stomach, 20-30% in the small intestine, 5% in the colon and rectum, less than 5% in the esophagus and sometimes develops outside the intestinal tract, in the abdominal cavity (**Nikolaos et al., 2005**).

There was considerable controversy as to the line of differentiation, since some tumors exhibited a myogenic phenotype, others showed neural differentiation, some revealed mixed differentiation and some cases did not show any specific line of differentiation, the ‘null phenotype’ (**Muna et al., 2005**).

GISTs were divided into four major types: smooth muscle; neural; combined smooth muscle-neural; and uncommitted. Recent studies have reported GIST cells demonstrating characteristics similar to those of the interstitial cells of Cajal (ICC), or ‘pacemaker cells’, which play a neuromotor role in normal gut motility (**Ken-ichi et al, 2006**).

GISTs also vary greatly in size, morphology, and malignancy potential, creating a continuum of neoplasms with uncertain malignancy potential ranging from virtually

benign tumors to overtly malignant, aggressive cancers. The more indolent GISTs are typically small, whereas other GISTs may present with overt metastases already at the time of the diagnosis (**Heikki,2006**).

GISTs typically arise in the bowel wall, usually from the muscularis propria, and may extend intra- or extraluminally (**Sullivan et al., 2006**).

GISTs arise from activating mutations in KIT or platelet-derived growth factor receptors α (PDGFR α) (**Michael,2006**). In the 1990s, investigators noted similarities between GIST cells and the interstitial cells of Cajal, a group of cells located in the muscularis propria and around the myenteric plexus throughout the GI tract,serving as pacemakers for peristaltic contraction (**Janeway et al., 2007**).

Immunohistochemically, the tumor cells revealed a phenotype similar to Cajal cells, occasionally with differentiation to smooth muscle cells or neural cells. Non-epithelial tumors originating from the gallbladder are rare. Among these, rhabdomyosarcoma, malignant fibrous histiocytoma, and angiosarcoma reportedly represent malignant mesenchymal tumors (**Makoto et al., 2005**).

Risk factors and aetiology are unknown, but there is a rare association with neurofibromatosis type. Some studies show no significant sex difference, whilst others show a male predominance.. Sporadic instances are rare before the age of

forty. However, GISTs can be familial, thus can be present in younger patients (*Sullivan et al., 2006*).

Primary GISTs may occur in locations other than gastrointestinal tract for example the first case of a large Primary gastrointestinal stromal tumor presenting as a uterine mass in a 77-year-old female. It is extremely rare that these tumors occur in the bile tract (*Makoto et al., 2005*).

It is generally accepted that the criteria needed for predicting biological behavior may differ significantly with location. For example, in the colon, size smaller than 2 cm and mitotic rate less than 1 mitosis /50 High power field (HPF) are indicators of benignity, while size larger than 5 cm and mitotic rate greater than 5/10 are generally accepted as predictors of malignancy (*Hillemanns et al., 2005*).

This lack of clarity in distinguishing GISTs can potentially affect clinical decision-making, because non-GISTs included in the differential diagnosis are sensitive to systemic chemotherapeutic treatment, whereas GISTs are resistant. Surgical resection was historically the only therapy with efficacy in true GISTs. However, even complete surgical resection of primary GIST carried a substantial risk for recurrence (*Charles, 2006*).

The clinical presentation of GIST is erratic. Furthermore, only 70% of the patients are symptomatic, while 20% are asymptomatic and 10% are detected at

autopsy. **(Kim et al., 2005).**

GISTs evaluation can be done with many imaging methods like: ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission transverse tomography (PETT). CT-scan can detect small intestinal tumors and guide the biopsy, it is an accessible and sensitive method especially in case of liver metastasis and also provides useful information about the response to the treatment and about the recurrence **(Rosenbaum et al., 2006).**

Surgery is the mainstay of therapy for non metastatic GISTs. Lymph node metastasis is rare and routine removal of lymph nodes is typically not necessary, also wide margins are not necessary. Laparoscopic surgery has been shown to be effective for removal of these tumors without the need of large incisions **(Nguyen et al., 2006).**

The tyrosine kinase inhibitor Imatinib (Glivec/ Gleevec), a drug initially marked for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases. Patients who become refractory on Imatinib may respond to the multiple tyrosin kinase inhibitor sunitinib (Sutent) **(Eisenberg et al., 2009).**

Overall survival (OS) at 5 years for patients with GISTs has been reported to be 19% to 56% from various series. Complete resection has a major effect on survival. This was true even when achieving a complete resection involving the resection of multiple adjacent organs. Tumor grade was the second major factor that had an effect on survival and recurrence. (*Nguyen et al., 2006*).

Close follow-up with abdominal and pelvic computed tomography scanning beyond the usual 5- year is essential (*Dematteo et al., 2000*).